Biosante Pharmaceuticals Inc  

(Public, NASDAQ:BPAX)   Watch this stock  
Find more results for bpax
1.14
-0.01 (-0.87%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.14 - 1.18
52 week 1.01 - 3.65
Open 1.15
Vol / Avg. 135,599.00/147,376.00
Mkt cap 27.92M
P/E     -
Div/yield     -
EPS -1.32
Shares 24.49M
Beta 1.25
Inst. own 10%
Jun 19, 2013
BIOSANTE PHARMACEUTICALS INC Special Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 12, 2013
BIOSANTE PHARMACEUTICALS INC Extraordinary Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -202.65% -1204.73%
Operating margin -202.65% -1210.03%
EBITD margin - -995.88%
Return on average assets -39.02% -54.81%
Return on average equity -52.90% -84.00%
Employees 23 -
Carbon Disclosure Rating - -

Address

111 Barclay Boulevard
LINCOLNSHIRE, IL 60069
United States - Map
+1-847-4780500 (Phone)
+1-847-4789152 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's products either approved or in clinical development, include LibiGel, Male testosterone gel, The Pill-Plus and Elestrin. BioSante's products for female sexual health, menopause, contraception and male hypogonadism include its gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen. BioSante's gel products are designed to be absorbed quickly through the skin after application on the upper arm for the women's products, delivering the active component to the bloodstream evenly and in a non-invasive, painless manner. In February 2013, Aduro BioTech, Inc. acquired GVAX assets from BioSante.

Officers and directors

Louis W. Sullivan M.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Stephen M. Simes Vice Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Phillip B. Donenberg CPA Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 51
Bio & Compensation  - Reuters
Fred Holubow Independent Director
Age: 73
Bio & Compensation  - Reuters
Ross Mangano Independent Director
Age: 66
Bio & Compensation  - Reuters
John T. Potts Jr., M.D. Independent Director
Age: 80
Bio & Compensation  - Reuters
Edward C. Rosenow III, M.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Stephen A. Sherwin M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters